Two years of Truvada for pre-exposure prophylaxis utilization in the US

INTRODUCTION: Truvada(®) (TVD) was approved in July 2012 by the US FDA for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in high-risk adults. This study explores the characteristics of US PrEP users and their prescribers over th...

Descripción completa

Detalles Bibliográficos
Autores principales: Flash, Charlene, Landovitz, Raphael, Mera Giler, Robertino, Ng, Leslie, Magnuson, David, Bush Wooley, Staci, Rawlings, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P198
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225421/
https://www.ncbi.nlm.nih.gov/pubmed/25397476
http://dx.doi.org/10.7448/IAS.17.4.19730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225421/
https://www.ncbi.nlm.nih.gov/pubmed/25397476
http://dx.doi.org/10.7448/IAS.17.4.19730

Ejemplares similares